FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014093910> ?p ?o ?g. }

• W2014093910 abstract "The unique Polo-like kinase family member, PLK4, was identified as a novel therapeutic target for breast cancer through a systematic approach that integrated functional RNAi viability profiles with molecular profiling data. PLK4 is a conserved upstream regulator of centriole duplication that is aberrantly expressed in several tumor types. Dysregulation of PLK4 activity causes loss of centrosome numeral integrity, thereby promoting genomic instability, but could also enable cancer cells to tolerate its effects. A drug discovery program was initiated that resulted in the identification of CFI-400945, a first-in-class, potent and selective PLK4 small molecule inhibitor (IC50 = 2.8 nM, Ki = 0.26 nM). CFI-400945 is highly selective towards other PLK family members (PLK1, PLK2 and PLK3 IC50s >50 µM) and numerous other protein and lipid kinase classes. Consistent with PLK4 loss-of-function studies, cancer cells treated with CFI-400945 exhibit dysregulated centriole duplication, mitotic defects and cell death. Oral administration of CFI-400945 as a single agent once daily to mice bearing human cancer-derived cell line xenografts and patient-derived xenografts (PDX) results in significant inhibition of tumor growth at doses that are well-tolerated. Superior antitumor activity in vivo is observed towards PTEN-deficient tumor models compared to PTEN wild-type tumor models. Analysis of tumor xenografts from CFI-400945-treated mice demonstrated an increase in tumor cells with aberrant mitoses compared to vehicle-treated mice, and is consistent with observations from cell culture experiments. Together, these pharmacologic results support observations from functional genetic screening that inhibition of PLK4 kinase activity is lethal for PTEN-deficient cancer cells, and suggest a new mechanism-based approach for the treatment of patients whose tumors have defective PTEN. PLK4 dysregulation may represent an adaptation cancer cells have made to tolerate the effects of genomic instability induced by loss-of-function of PTEN or other mediators, such as TP53, ATM, BRCA1 and BRCA2, and thereby is a vulnerability that may be exploited for the design of cancer cell-selective therapies. The CTA to Health Canada for CFI-400945 received approval in July 2013, and an IND has been filed at the FDA, clearing the way for clinical evaluation of the molecule in the near future.Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B267.Citation Format: Jacqueline M. Mason, Dan C.-c. Lin, Xin Wei, Yi Che, Yi Yao, Reza Kiarash, Graham C. Fletcher, Mark R. Bray, Guohua Pan, Tak W. Mak. Inhibition of PLK4 as a therapeutic strategy for genomically unstable cancers deficient for PTEN. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B267." @default.
• W2014093910 created "2016-06-24" @default.
• W2014093910 creator A5000800493 @default.
• W2014093910 creator A5001045256 @default.
• W2014093910 creator A5001981134 @default.
• W2014093910 creator A5009372910 @default.
• W2014093910 creator A5042635125 @default.
• W2014093910 creator A5043711845 @default.
• W2014093910 creator A5047578921 @default.
• W2014093910 creator A5060289952 @default.
• W2014093910 creator A5083257412 @default.
• W2014093910 creator A5086399826 @default.
• W2014093910 date "2013-11-01" @default.
• W2014093910 modified "2023-09-27" @default.
• W2014093910 title "Abstract B267: Inhibition of PLK4 as a therapeutic strategy for genomically unstable cancers deficient for PTEN." @default.
• W2014093910 doi "https://doi.org/10.1158/1535-7163.targ-13-b267" @default.
• W2014093910 hasPublicationYear "2013" @default.
• W2014093910 type Work @default.
• W2014093910 sameAs 2014093910 @default.
• W2014093910 citedByCount "1" @default.
• W2014093910 countsByYear W20140939102014 @default.
• W2014093910 crossrefType "proceedings-article" @default.
• W2014093910 hasAuthorship W2014093910A5000800493 @default.
• W2014093910 hasAuthorship W2014093910A5001045256 @default.
• W2014093910 hasAuthorship W2014093910A5001981134 @default.
• W2014093910 hasAuthorship W2014093910A5009372910 @default.
• W2014093910 hasAuthorship W2014093910A5042635125 @default.
• W2014093910 hasAuthorship W2014093910A5043711845 @default.
• W2014093910 hasAuthorship W2014093910A5047578921 @default.
• W2014093910 hasAuthorship W2014093910A5060289952 @default.
• W2014093910 hasAuthorship W2014093910A5083257412 @default.
• W2014093910 hasAuthorship W2014093910A5086399826 @default.
• W2014093910 hasConcept C10447061 @default.
• W2014093910 hasConcept C121608353 @default.
• W2014093910 hasConcept C184235292 @default.
• W2014093910 hasConcept C190283241 @default.
• W2014093910 hasConcept C2777609662 @default.
• W2014093910 hasConcept C29537977 @default.
• W2014093910 hasConcept C502942594 @default.
• W2014093910 hasConcept C54355233 @default.
• W2014093910 hasConcept C86554907 @default.
• W2014093910 hasConcept C86803240 @default.
• W2014093910 hasConcept C93304396 @default.
• W2014093910 hasConcept C95444343 @default.
• W2014093910 hasConcept C96232424 @default.
• W2014093910 hasConceptScore W2014093910C10447061 @default.
• W2014093910 hasConceptScore W2014093910C121608353 @default.
• W2014093910 hasConceptScore W2014093910C184235292 @default.
• W2014093910 hasConceptScore W2014093910C190283241 @default.
• W2014093910 hasConceptScore W2014093910C2777609662 @default.
• W2014093910 hasConceptScore W2014093910C29537977 @default.
• W2014093910 hasConceptScore W2014093910C502942594 @default.
• W2014093910 hasConceptScore W2014093910C54355233 @default.
• W2014093910 hasConceptScore W2014093910C86554907 @default.
• W2014093910 hasConceptScore W2014093910C86803240 @default.
• W2014093910 hasConceptScore W2014093910C93304396 @default.
• W2014093910 hasConceptScore W2014093910C95444343 @default.
• W2014093910 hasConceptScore W2014093910C96232424 @default.
• W2014093910 hasLocation W20140939101 @default.
• W2014093910 hasOpenAccess W2014093910 @default.
• W2014093910 hasPrimaryLocation W20140939101 @default.
• W2014093910 hasRelatedWork W2545867 @default.
• W2014093910 hasRelatedWork W26070129 @default.
• W2014093910 hasRelatedWork W27742284 @default.
• W2014093910 hasRelatedWork W28597462 @default.
• W2014093910 hasRelatedWork W29497872 @default.
• W2014093910 hasRelatedWork W3962595 @default.
• W2014093910 hasRelatedWork W4892554 @default.
• W2014093910 hasRelatedWork W7366388 @default.
• W2014093910 hasRelatedWork W11701208 @default.
• W2014093910 hasRelatedWork W16813516 @default.
• W2014093910 isParatext "false" @default.
• W2014093910 isRetracted "false" @default.
• W2014093910 magId "2014093910" @default.
• W2014093910 workType "article" @default.